Anti-Orai1 Antibody
First Claim
Patent Images
1. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of an amino acid sequence represented by any one of SEQ ID NOs;
104, 106, 107, and 108, and the CDRH3 consists of an amino acid sequence represented by SEQ ID NO;
109 or 110; and
the light chain sequence comprises a variable region having CDRL1, CDRL2, and CDRL3, wherein the CDRL1 consists of an amino acid sequence represented by any one of SEQ ID NOs;
93, 94, and 95, the CDRL2 consists of an amino acid sequence represented by any one of SEQ ID NOs;
96, 97, and 98, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101.
0 Assignments
0 Petitions
Accused Products
Abstract
It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
-
Citations
34 Claims
-
1. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
102, the CDRH2 consists of an amino acid sequence represented by any one of SEQ ID NOs;
104, 106, 107, and 108, and the CDRH3 consists of an amino acid sequence represented by SEQ ID NO;
109 or 110; andthe light chain sequence comprises a variable region having CDRL1, CDRL2, and CDRL3, wherein the CDRL1 consists of an amino acid sequence represented by any one of SEQ ID NOs;
93, 94, and 95, the CDRL2 consists of an amino acid sequence represented by any one of SEQ ID NOs;
96, 97, and 98, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO;
101. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO;
-
29. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the concentration at which the amount of IL-2 released from Jurkat cells treated with PMA and A23187 is inhibited by 50% is 80 ng/mL or lower.
- View Dependent Claims (30)
-
31. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the concentration at which the amount of IL-2 released from human peripheral blood mononuclear cells treated with PMA and A23187 is inhibited by 50% is 100 ng/mL or lower.
- View Dependent Claims (32)
-
33. An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the concentration at which the amount of IFN-γ
released from human peripheral blood mononuclear cells treated with PMA and A23187 is inhibited by 50% is 800 ng/mL or lower. - View Dependent Claims (34)
- 2, wherein the concentration at which the amount of IFN-γ
Specification